For the millions of individuals suffering from diabetes, there may finally be a solution through stem cell therapy. SERAXIS’ team of top scientists has successfully developed state-of-the-art technologies for the treatment of insulin-dependent diabetes. The patented stem cell derived-replacement therapy, SR-01 is able to normalize blood glucose over a long term in animal models of diabetes and will soon be tested in the clinic.

SERAXIS, INC., a regenerative medicine biotech company was launched in 2013 and operates from the Germantown Innovation Center, Germantown, Maryland. Its name SERAXIS (SER-AXIS) originates from the words serum and praxis (from Greek, putting a theory into practice) to reflect the company’s mission to develop a clinical treatment for use in medicine. 

How MSCRF Helped

MSCRF provided a 12 month-grant to support some of the research work necessary to bring the therapy to the clinical stage. This work focuses on the in vivo long-term efficacy and safety of SR-01. MSCRF is well connected throughout the field of regenerative medicine. MSCRF has helped raise the visibility of Seraxis, connected the company to interested investors, and assisted with talent recruitment.